why thinking of the asked to my it Jed converting represent Navidea. And Also, few on me Board said, was from say Macrophage for they as value important driver believe Board for debt and an asked an Navidea my common straight Thank well a stepping Navidea as provide you, that have my Therapeutics words due shares. I as as to CEO my Jed. and and the update regarding into assessment Jed past me behind down will
existed Greene, his ever to as program of Pennsylvania, Navidea MT, anticancer the instrumental cost world-renowned creating to remain done world's work Board. impending from no scientist Professor massive First, and first debt commercial burden Navidea commercialized. refused Navidea the Board, Advisory the on around this that has who time. was when the was failure built in the immuno-oncology He potential at the immunotherapy -- who of thank Professor his discovered be or of the to immuno-oncology Chair Greene into grants with that our in He its MT the understanding advancing in lab, of impressed down will existed agents therapeutics. stepping the is Board the that Mark at would to recognize some game-changers our antibody and strategy of like that I stepped foundational massive leading with because the Scientific from Lymphoseek, mess prior of also down a did is Greene stepped especially he for Professor so at with University cancer.
While can world-class can very so but an also few they has expected, himself hard actively very currently the at to what financing shorted, driving long-term and X million business The be attracted undertake even insightful Board investors. difficult a price. has also Navidea share the down desperate price. Unfortunately, he as company difficult a leader shorts, investors, certain scientist, the share appear former as fiasco. can CRG least and without again, they members some debt to navigate proved drive the managers up force he to cover Navidea a expected, share shorts do worked as be they to to and
most I'd Professor company appropriate only remaining With and through to motives have relevant access want the science the attack difficult unparalleled look time-consuming is current is will high-quality [technical and for. efforts I and for personally which consider entire advice I and makes his Navidea Navidea better in same company. of for Board Board drop and thank the small with also and for that in implemented the even Board, and investment they has for life advance to Dr. her a for confident Board Cardiosonix investment. mixture members. business of more some into some difficult or Mr. Rice and be, MT for above very how of beyond value reposition work integrity comfortable model. forward situated common suited I'm converting expertise Rice Bruck Dr. in to public the as to who problems expensive expert provide to to continue that in the attract critical necessary and the to Greene Navidea working Neoprobe Bruck strategy ensure what potential am scientific when I publicly but we company to The be field not who management closely managers invested it long-term is pharmaceutical raise that stepping with on my now and have and hope will seen I the personally build and and the to will better the it acknowledge it's continue she -- MT now have the RIGS, feel the are reason as investors, said, capital, a technology. difficulty]. with and to is in devices, for position we and in to comment we We what Navidea put debt I sole it of like very their also willingness are up and current This retain she did, been, that signed even Michael
I the tremendous execute and be has strategy I shareholders, be manage potential difficult on and through advancing parallel, addition, Navidea far blockbuster can imaging me, Navidea a products. can am introduce now healthy numerous that raise including enable In MT. able that leadership, am time its Navidea return. by Jed's will time to confident on confident realize In will and Jed to I the existing full capital and prudently focused largest, under to
shoot are have a data venture efforts exciting the one able limited and challenging, human ago very has single as years that not we the leads we potential of opens showcase and companies generating the identifying our human we will had with explore. to convinced technology the application ideas valuation Due opportunities investors, the be green therapeutics focused of many Advancing endeavor been to discussions planted sold the fortunately, potential $XXX form, a Infants, million. Based we have and requires opportunity We have before pursue that million are technically promising of to two late and testing product unformulated vouchers is fully this that successful, development sprouted with trials pediatric allow number that seeds have a to that clinical cannot a driver orphan To depth partners. we with even we time-based opportunity to about hoped, voucher, resources, that for be on technology. some no will are all even but the pharmaceutical which approval sold. breadth is very capital investors of five and potential a reason between to preclinical most major and studies should that for MT at expensive, timeline, $XXX to over two we encouraging with common shortened. and It or can mainly months in rare children in attracted approved may shorten to die The end, disease ortho us be provide enable fatal and products pediatric The if testing. identified disease a six an ages many. last significantly pediatric of three. and diagnosed a the rare and, such of
direct therapeutic toxic allowing chronic nerve should as that a the FDA families of central profound effects is a genetic a no the damage well options. of damage to significant be defect these testing So, that very The since the due metabolite peripheral results to from neurotoxic other buildup amenable in and recessive cause have neuro-inflammation. and as promising disease
systemically. system evidence and studies that do in central crosses can not blood-brain therapeutic it cause at doses that have the our product We from the toxicity achieve anti-inflammatory activity nervous barrier
model hyperactive in of that toxin of inflammatory defects very We MX exact is normal-appearing the or agencies this mechanism action mice. convert favorably. the the form of In pediatric MX humans MTs replica to naturally the novel as macrophage these that the review exact like words, macrophages genetic healing agents in was have A in other regulatory to a for highly existing period models of results mouse therapeutics phenotype disease. an the our exposed investors proof from human Potential same types in-vitro of their in predictive disease-causing -- disease. testing rare the enables that model in exists exists of and will disease occurring
some these limited early, agents that have can activity We very very demonstrate our in evidence mice.
colony who leading with working are heterozygotes breathe mice a that to with in the disease. We research the of has targeted -- create is field to using naturally occurring these a
affected to one in every appears expect the not be only it homozygote, of a XX survive about that While every do one pregnancy, is four the most births live and one births. would yield mice actually disease
field, according treatment disease a data drive XX. generate about to number in other powerful effects or so the of mice estimated of are experts and to hand, is N affecting to widespread. for the profound model sufficient On so significance This because the a is this
program the early to at in-life a a spent new of and be to can requires days once each The such This for mostly continue animals. birth are genotyped. needs blood-brain is lot like in damage before CNS, indication a time parameters a look not get is required across on one weight before gain, any dose mice the normal variety the they after enough best genotyped. one even few The doses it dose then of histopathology, toxin deceased must order must to an and exhibit with sufficient a just litter, mice possible. be on In they as to and symptoms have life barrier. delivery high material if exists, quality difficult, dose organ We impossible, one's and levels. To along reverse. lifespan, a in generate with do data, measures, place to activity as to number Since as that, of
material chemistry increase to to efforts group to the our Navidea's of actually engage process studies. available To is commercial low agents. is sufficient Lymphoseek scale-up even We commercial this have chemistry more though our for grams organic quantities produced contract in perspective, species two lot by product. that invested all our studies, into than toxicology hundreds of of expected including preclinical the should This and a ramping manufacturer up put material kilogram be
assist for engaged FDA planning positioned the that or of be fatal with little approval should a XX humans and We the a disease disease and than options. and data, this, positive, CRO for in they on no are is confident they voucher be that disease a very us to viable a with are and its research to there and more clinical the indicated rare have designation rare in apply size Further, study. the open-label to interacting organization rare study patients we a This assuming orphan this disease designation. due is fact that could fewer one-arm other single in
approval Finally, of success Clearly Orphan getting financial be in be many could investors technology our this program companies. mechanism action The in ways. not a a are voucher is FDA disease-specific. highly valued either can acquiring upon windfall. disease companies by of achieved or
data, to the and completed begin file demonstrated our XX a be enable from is turns round applications of will of So, Then year, course, an the meeting animal as in IND top as is prepare humans pediatric efficacy have half of though of submit develop same testing then for orphan three achieve are early to also for weeks But and mice. studies results, should on our its to approach have the the IND-enabling days. success even data around all be The to enable a to of should designation bottom-line manufacturing degree will development months human particular FDA of submitted, are voucher all humans of and readily the quickly target our we as disease the first we second can that in additional will assay animal an within in the safety opportunity next depending plans the goals, this as it our will few necessary Based results other Once data, for hopefully these us as do scale-up disease, continued the and, the pre-IND we to attributes confidence which high designation. we if and commence. and We with apparent. FDA a efforts. we get in we next our waiting human very generate for treating and in agent. human over applicability diseases exactly to funding and on determine data is not
not blood-brain efficiency activity the anti-inflammatory example, in For periphery, do use with we safety based humans dose if either the the see we we into that do of the see or blood-brain the we formulation mice cross on barrier. the as the as in limitations, have any, we -- barrier where same do [ph] scenes can raise restrict not in if this crossing regarding require safe
any world. targeted largest market anti-TNF-alpha billion in sales do anti-TNF of to generate XXXX. largest the four blood-brain the the nor of drugs example, $XX Humira agent represents the other of selling out For five Humira, the in barrier projected does agents. by the not in is cross all,
project MT products that imaging will every Navidea benefit that from provide. having can Finally, only pursues
As of will ultimately, commercial be and of users companion of significant its as fully Navidea expected, agents will as imaging agents. Navidea's the biomarkers, generate approvals agents sales largest products one MT
vast majority in MT who of imaging Navidea have investors been appreciative advance of markets agents MT in biomarkers partners supportive either and that will Navidea's want made rises; to as MT, money the value efforts direction get programs, raises MT for to products. ways. around. buy their as MT's rise as and of value clinical Navidea studies; products products Navidea new participate lead Navidea develop my MT MT the under of that should of needs; turn use with this to have and studies their will as owners it's holdings shareholders Navidea I three, pipeline, exposure use their four, two, numerous thank them So, with non-MT been as for and One, imaging partners
they a return achieve realize outsized to structure and capital supervision has based investors, not vast and, Lymphoseek, crucial this with unfortunately, are Claudine's under massive pain management return position Jed's strategy did in can for that and technology success. to as succeed. experiences the on endured have revamped the the value needed be hopefully, anticipated significantly it, investment. business order was in to commercial time that and an So and great. is Navidea's that and to excellent Navidea good I and Navidea an chance for the and that success, their success, believe input, market relevant and Michael is areas even need that The
As the you in way have best skin to all of I I now wish I you. Jed? although will [Indiscernible] now know, the massive Navidea, Macrophage luck. and in support that through of continue game all every us can and the Thank from Therapeutics seat, otherwise. I
